INTRODUCTION
The prognosis for children born with congenital heart disease (CHD) has improved dramatically over the last century. Prior to the availability of surgical techniques to palliate complex CHD, the estimated 1-year survival for these patients was between 0 and 36%, and very few patients survived to adulthood [1] . Today, the expected long-term survival of CHD patients is greater than 90% [2 & ]. Pediatric cardiologists must now not only provide early, postnatal care for CHD patients, but also must address issues that affect long-term morbidity and mortality, such as: neurodevelopmental disability (NDD), respiratory disease, renal dysfunction, arrhythmia, heart failure, pulmonary hypertension and an increased risk of cancer [3] [4] [5] [6] 7 & ]. The increased incidence of these comorbidities in CHD patients compared with the non-CHD population has prompted research into genetic causes of CHD that may also contribute to these comorbid conditions.
Studies of CHD in monozygotic vs. dizygotic twins, the recurrence of CHD in siblings of patients affected by CHD, and pedigree analyses of families with recurrent CHD across generations all suggest a genetic contribution to CHD [8] [9] [10] . Approximately
THE GENETICS OF CONGENITAL HEART DISEASE
Genetic changes associated with CHD include aneuploidy, copy number variations, and point mutations. These mutations can be inherited within a family following the laws of Mendel, known as Mendelian inheritance, or occur for the first time in the affected patient (sporadic or de novo mutations). Inherited mutations have differing degrees of penetrance, a term that refers to the proportion of individuals carrying a mutation that also demonstrate the associated disease, and varying expressivity, referring to the range of phenotypes associated with a given mutation. Each of these types of genetic change, as well as the effect of inheritance and penetrance are depicted in Fig. 1 and are discussed more fully in the following section.
Aneuploidy and copy number variant mutations
In cases of aneuploidy, the genetic defect is an abnormal number of chromosomes or segments of chromosomes. This can be either due to the presence of an additional chromosome, such as Down syndrome (Trisomy 21), the absence of a chromosome, such as Turner syndrome (monosomy X), or deletion or duplication of one arm of a chromosome such as Cri du chat syndrome (5p-). The incidence in liveborn infants with CHD is 9-18% [12, 13] . Although some aneuploidies have strong associations with particular malformations (such as atrioventricular septal defects with Trisomy 21 [14] ), the range of CHD associated with aneuploidy is quite broad. Common aneuploidies associated with CHD are detailed in Table 1 .
Copy number variation (CNV) refers to deletions or duplications of segments of chromosomes. They are estimated to cause 10-15% of CHD and common CNV mutations associated with CHD are listed in Table 1 [36 & ]. They are usually de novo mutations, but can also follow patterns of Mendelian inheritance. Del22q11 (also known as DiGeorge syndrome or Velocardio-facial syndrome) was one of the first CNV mutations to be associated with CHD. The deletion alters the expression of a key transcription factor TBX1, that results in the abnormal development of the pharyngeal arches and pouches leading to the clinical manifestations of the syndrome [37, 38] . These manifestations include CHD, hypocalcemia due to absence of the parathyroid glands, immunodeficiency due to thymic aplasia, characteristic facial features, and neurodevelopmental abnormalities. There is significant heterogeneity, however, of clinical phenotypes among patients with del22q11, including between monozygotic twins with identical deletions [39] .
Point mutations, Mendelian inheritance and de novo mutations
Point mutations alter the nucleotide sequence of a particular gene. In some cases, the change is inconsequential, causing no significant change to the amino-acid coded by a particular codon (series of three nucleotides within a gene that identify which amino acid is inserted during protein synthesis). Some point mutations, however, dramatically alter
KEY POINTS
Genetic mutations can be identified in 35% of patients with congenital heart disease. These mutations include aneuploidy, copy number variant mutations, and point mutations. They may be inherited through Mendelian inheritance of occur de novo.
Genetic causes of congenital heart disease also account for many of the comorbidities seen with increased frequency in congenital heart disease patients, including neurodevelopmental disability, pulmonary disease, arrhythmia, renal disease, heart failure and an increased incidence of malignancy.
Several testing modalities are available to evaluate for genetic causes of congenital heart disease. These include general tests such as karyotype, chromosomal microarray, and whole exome sequencing and targeted testing that identifies only specific mutations such as fluorescent in-situ hybridization and targeted genetic sequencing.
A patient's clinical findings and family history are the most important elements to consider whenever deciding which genetic tests are most appropriate.
Clinicians are encouraged to utilize consultation with clinical geneticists and genetic counsellors in order to ensure efficient genetic testing and appropriate counselling of patients about the results of genetic testing.
protein structure and function by inserting either: a 'stop' codon that prematurely terminates gene transcription; a 'loss of function' mutation that significantly decreases the function of the protein through the insertion of a different amino acid in a critical region of the protein; or a 'gain of function' mutation that results in abnormal upregulation of protein function.
It is estimated that approximately 2% of CHD is due to inherited point mutations. Such mutations most commonly affect genes for cardiac transcription factors, signaling molecules or cellular structures without significantly reducing reproductive potential [40, 41] . For example, mutations in the NKX2.5 gene, a critical transcription factor that specifies cardiac mesoderm during embryogenesis, were some of the first mutations associated with inherited CHD. Its role in CHD, was discovered through pedigree analysis of families with atrial septal defects (ASD) and conduction disorders. Genotype-positive individuals, that is those who carried this mutation, had one of the three phenotypes: isolated ASD; isolated conduction defects; or ASD with conduction defects [42] . De novo mutations account for approximately 10% of CHD and their incidence has been stable over time. These mutations confer a reproductive disadvantage to affected individuals, with new Table 1 . Congenital heart disease due to common aneuploidy and copy number variation mutations The next section will show that mutations affecting these pathways provide a genetic explanation not only of CHD but also for the of some of the comorbidities that affect longterm outcomes in CHD patients.
CLINICAL IMPLICATIONS OF GENETIC CAUSES OF CONGENITAL HEART DISEASE
Three representative examples of comorbidities seen in CHD that have a common genetic origin with CHD are NDD, respiratory disease, and myocardial dysfunction. This section explores each of these comorbidities in detail with a focus on the clinical implications of their genetic origin.
Neurodevelopmental outcomes in congenital heart disease
Epidemiological studies have found that 10% of all CHD patients and 50% of patients with severe CHD have NDD [4] . Although clinical factors such as duration of deep hypothermic circulatory arrest at the time of surgical repair, duration of ICU stay, and preoperative compromise of cerebral perfusion and oxygenation have been causally implicated in CHD-NDD, there is increasing evidence of a genetic contribution to neurodevelopmental outcomes. For example, Limperopoulos et al. [49] found that preoperative NDD and microcephaly, both of which may be caused by a genetic syndrome, independently predicted neurodevelopmental outcomes in CHD patients.
One potential explanation for the dual effect of a genetic mutation causing both CHD and NDD, is altered chromatin remodeling, a critical process in regulating gene expression. Mutations affecting this process have the potential to affect the formation of multiple organ systems. Homsy et al. showed this in a study of ,213 performed CHD trios (patient þ unaffected parents) inclusive of CHD patients with and without NDD. They performed whole exome sequencing (WES) on the trios and identified de novo mutations in the CHD patients. They then compared these mutations to de novo mutations identified in cohorts of patients with NDD but without CHD. This identified 69 overlapping mutated genes that were present in both the CHD and the isolated NDD cohorts, many of which were mutations in genes affecting chromatin remodeling. When they compared the CHD patients with NDD to those without NDD, CHD patients with mutations in one of the overlapping 69 genes had a higher incidence of comorbid NDD thus identifying a potential genetic link between CHD and NDD [43 & ].
The potential for a common genetic mutation to cause both CHD and NDD has significant implications for neurodevelopmental screening and intervention in CHD patients. In 2012, the American Heart Association published a review of neurodevelopmental outcomes in CHD [4] . This review includes recommendations for screening for NDD in CHD patients. According to these guidelines, clinicians should risk stratify CHD patients into high-risk and low-risk groups. Congenital heart disease patients with suspected genetic abnormalities or syndromes associated with NDD are stratified to the high-risk group and should be referred for both early intervention services and formal developmental assessment. Thus, appropriate genetic testing has the potential to improve outcomes for patients whose CHD is due to a genetic cause that also increases their risk of NDD by allowing for early intervention services that have a clear documented benefit in improving patient outcomes and decreasing the morbidity associated with NDD [50] .
Respiratory disease and congenital heart disease
Respiratory comorbidities cause significant morbidity and mortality in the CHD population. Congenital heart disease patients demonstrate both an increased risk of death due to pneumonia and an increased incidence of moderate-to-severe impairment in lung function [3,51 && ]. Similar to NDD associated with CHD, recent research has demonstrated common genetic pathways affecting both cardiac formation and respiratory status, particularly the role of cilia in embryonic development and postnatal organ function.
Cilia are hair-like structures found on the surface of most cells. They have a variety of functions both in development and in postnatal life, including: leftright organization of the embryo, development of the cardiovascular, renal, and neurologic systems, and postnatal function of the neurologic, reproductive and respiratory systems. During embryogenesis, mutations that compromise cilia function result in heart defects within the heterotaxy spectrum of CHD, as well as a number of other congenital malformations [48] . During postnatal life cilia mutations affect respiratory function through impaired clearance of respiratory secretions, a condition known as primary ciliary dyskinesia (PCD). This leads to recurrent pulmonary infections and a progressive decline in pulmonary function, and 6.5% of patients clinically diagnosed with PCD have concomitant cardiac defects within the heterotaxy spectrum of CHD.
Recognition of PCD in the context of CHD is challenging and requires a high degree of clinical suspicion. Patient history can suggest the diagnosis, particularly if there is a history of unexplained neonatal respiratory distress, situs inversus with respiratory symptoms, unexplained bronchiectasis or recurrent otitis media occurring with lower respiratory infections [52] . Testing for PCD includes: electron microscopy, video microscopy, and genetic evaluation. Each of these modalities can provide a component of the diagnosis, but each has limitations. Electron and video microscopy evaluate a patient's cilia for structural and functional abnormalities. Electron microscopy is useful if patients have abnormal cilia ultrastructure, however, it fails to make a diagnosis in the 30% of PCD patients who have normal cilia structure. The combination of electron microscopy and high-speed video microscopy can definitively rule out PCD if ciliary function is normal, but cannot differentiate between PCD and secondary ciliary abnormalities due to inflammation or infection of the nasal or bronchial epithelium. Genetic testing looks for mutations in 1 of 35 genes known to cause PCD and makes a definitive diagnosis of PCD in 65% of PCD patients [52, 53] . Given the limitations of each testing modality, clinicians must make the diagnosis by considering not only testing results, but also the clinical history of the patient.
Once PCD is identified, a number of interventions are available to improve long-term outcomes in affected CHD patients. For example, PCD patients undergoing cardiac surgery are known to have an increased risk of postoperative pulmonary complications (pneumonia, atelectasis, failure to wean from a ventilator, etc). This risk can be minimized by ensuring optimization of preoperative pulmonary function, aggressive postoperative pulmonary toilet, and (when possible) early extubation following surgery [54] . Similarly, vaccination and the early use of appropriate antibiotics can lessen the severity of pulmonary infection in patients with PCD and potentially slow the decline of pulmonary function in these patients [3] .
Heart failure in congenital heart disease Approximately 25% of CHD patients have significant heart failure by the age of 30 [55] . The mechanisms and clinical circumstances that lead to heart failure in CHD patients differ from those leading to heart failure in patients without CHD. There are very few studies examining the cause and optimal management of CHD-related heart failure. The absence of such studies, has left clinicians to extrapolate treatment decisions for CHD patients from guidelines developed from studies of patients with non-CHD heart failure [56] . Unfortunately, the benefits demonstrated in the non-CHD heart failure management trials have not been replicated in the few studies of these management strategies for CHD-heart failure [57, 58] .
The need for treatment specific to CHD-related heart failure has prompted studies of genetic mutations that contribute both to CHD and cardiac dysfunction [6] . These studies have focused on genes with critical roles in embryonic cardiac formation and postnatal cardiac function such as MYH6. The MYH6 gene codes for the sarcomeric protein, myosin heavy chain 6 and is expressed during both fetal and postnatal life. MYH6 mutations are increasingly recognized to contribute to heart failure in the context of CHD [59, 60] . Theis et al. studied a cohort of patients with hypoplastic left heart syndrome (HLHS) who developed systemic right ventricular failure following Fontan palliation. Sequencing affected patients revealed compound heterozygosity for recessive MYH6 mutations, whereas unaffected family members carried only one copy of the mutated gene [61] . As more mutations are identified which cause both CHD and cardiac dysfunction, clinicians will be able to better identify CHD patients at high risk for subsequent heart failure, who will benefit from increased surveillance for heart failure and early interventions to address complications of heart failure.
To summarize, this section examined three CHD-related comorbidities that share a common genetic origin with CHD: NDD, respiratory comorbidities, and CHD-related heart failure. Many other comorbidities are also seen in CHD patients, and investigations into genetic causes of these conditions is ongoing. The next section provides a clinical algorithm for clinicians to use whenever considering a genetic evaluation of a CHD patient.
GENETIC TESTING IN CONGENITAL HEART DISEASE PATIENTS
In order to initiate appropriate and cost-efficient genetic testing of CHD patients, clinicians must be familiar with available genetic tests and their clinical indications. [62] . Whole exome sequencing is the most comprehensive test currently available. It evaluates a patient's entire exome for point mutations and sometimes CNV mutations (not all testing protocols include CNV analysis). Whole exome sequencing may miss up to 5% of specific gene mutations, but its sensitivity continues to improve with time [62] .
Targeted testing modalities include fluorescence in-situ hybridization (FISH) and targeted sequencing, they are best suited to identify a mutation known to cause a specific genetic syndrome with a clear phenotype. FISH is used to identify aneuploidies and CNV mutations by using a fluorescent probe to visualize a specific gene or portion of a gene. FISH does not detect abnormalities other than the one the probe is designed to look for. Targeted sequencing of one or more genes evaluates specific genes for point mutations. One example of a syndrome in which targeted sequencing of a single gene is recommended is Marfan syndrome. Marfan syndrome is a connective tissue disorder that results from mutations in FBN1 (Fibrillin 1). Patients have an increased risk of arterial aneurysms and dissections and often have a number of distinctive musculoskeletal features including tall stature, scoliosis, long fingers, and flat feet. Targeted sequencing that identifies pathologic mutation of FBN1 is diagnostic and identifies patients that would benefit from annual surveillance for arterial aneurysms.
Clinical approach to genetic testing in congenital heart disease . The key to efficient and appropriate testing of CHD patients is the clinical context of the patient. Testing patients with either mild isolated CHD, without a family history of CHD, or with no significant comorbidities, is unlikely to provide a genetic cause of the CHD and is not currently recommended. Testing patients with complex CHD, a positive family history of CHD, comorbid congenital malformations, or other significant comorbidities, such as NDD, increases the likelihood of a genetic cause of the CHD and genetic testing is strongly recommended [4] .
Once the clinician decides to pursue genetic testing of a CHD patient, he or she must then decide whether targeted testing or general testing is most appropriate. If the clinical presentation, family FIGURE 2. Genetics screening algorithm for congenital heart disease patients (Previously Published Figure) 
The role of genetics consultation and genetic counselling
Genetics consultation can assist patients and clinicians in obtaining and understanding the results of genetic testing as it pertains to CHD. Clinical geneticists provide rigorous patient and family phenotyping and assist clinicians in selecting appropriate genetic testing modalities. They also assist in the interpretation of genetic test results, that can be particularly helpful when testing reveals a variant of unknown significance (VUS). These mutations are rare or novel variants that have not been previously reported in association with clinical disease. Methods to determine whether a VUS is pathogenic and the likely cause of a patient's CHD include: rigorous family phenotyping with targeted genetic sequencing, evaluation of the evolutionary conservation of the mutated allele, and the effect of the mutation on gene transcription and protein function. Mutations that are de novo or segregate with affected family members are more likely to be pathogenic than mutations that are seen with equal frequency in affected and nonaffected family members. Mutations that either occur in highly conserved regions of a gene, cause the introduction of a stop codon, or cause a loss of function mutation are all more likely to be pathogenic [63] . Genetic counselling is another service that clinicians may consider as part of the genetic evaluation of a CHD patient. Genetic counsellors are trained in counselling patients and families about genetic disease, the risk of disease recurrence in future offspring, and decisions about genetic testing both in the prenatal and postnatal time periods. Their service is complementary to that of the clinical geneticist. By utilizing both services, CHD patients, families, and the clinicians caring for them receive cost-effective testing designed to meet the clinical needs of CHD patients and their families [64] .
CONCLUSION
Care of CHD patients in the 21st century demands a comprehensive approach to patient care that includes not only surgical palliation of anatomical defects, but also proactive strategies to address the comorbidities that cause morbidity and mortality in CHD patients. The timely and efficient use of genetics evaluation of CHD patients continues to gain importance in the long-term care of CHD patients through the identification of patients at high risk for specific comorbidities. Clinicians are increasingly being asked to obtain basic genetics evaluation of CHD patients and incorporate the results of this testing in their management strategies. This review has provided an introduction to the genetics of CHD and its associated comorbidities as well as a clinical algorithm that clinicians can use to efficiently incorporate a genetics evaluation into the care of CHD patients.
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